Previous close | 32.52 |
Open | 32.60 |
Bid | 30.57 x 800 |
Ask | 31.60 x 1200 |
Day's range | 29.94 - 32.73 |
52-week range | 27.06 - 107.79 |
Volume | |
Avg. volume | 2,410,133 |
Market cap | 6.038B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 45.09 |
EPS (TTM) | 0.70 |
Earnings date | 17 May 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 50.15 |
Despite beating analysts' estimates during its latest quarter, Doximity (NYSE: DOCS) stock took another nosedive after results were released this week. Investors who like companies using technology to serve customers but who are rattled by the tech sell-off should spend some time getting to know Doximity. Here's why this emerging healthcare leader is worth a look right now.
Shares of Doximity (NYSE: DOCS) fell 10% on Wednesday after the digital networking platform for medical professionals delivered an earnings report on Tuesday, and forecast a revenue range for its current fiscal quarter that was below Wall Street's expectations. In its fiscal 2022 fourth quarter, which ended on March 31, Doximity's revenue jumped 40% year over year to $93.7 million. "We're proud to now serve over 2 million U.S. healthcare professionals, including over 80% of U.S. physicians and over 50% of physician assistants and nurse practitioners," CEO Jeff Tangney said in the earnings press release.